The use of rituximab for the treatment of recurrent or refractory Stage 3 or 4 non-Hodgkin's lymphoma

NHS Quality Improvement Scotland
Record ID 32002000514
Authors' objectives:

This Understanding HTBS Advice brochure explains to people who are not healthcare workers, particularly people with this cancer and their carers, how the HTBS Comment on rituximab has been created. Much of the information in this booklet comes from a leaflet published by NICE about the use of rituximab for the treatment of recurrent or refractory Stage 3 or 4 non-Hodgkins lymphoma (March 2002), which is available at

Authors' recommendations: HTBS supports the NICE Technology Appraisal Guidance stating that: - Rituximab is recommended for the treatment of stage 3 or 4 follicular NHL only when all other treatment options have been exhausted, and then only on the understanding that the oncologist who prescribes it ensures that the effects of the drug on each patient are systematically recorded in a single listing (known as a prospective case series). - Rituximab is not recommended for patients with stage 3 or 4 follicular NHL for whom other treatments are still available. It is recommended as a last-line treatment and then only as part of the prospective case series as described above.
Authors' methods: Overview
Project Status: Completed
Year Published: 2002
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Scotland, United Kingdom
MeSH Terms
  • Rituximab
  • Lymphoma, Non-Hodgkin
  • Recurrence
  • Drug Therapy
  • Treatment Outcome
  • Antibodies, Monoclonal
  • Antineoplastic Agents
Organisation Name: Health Technology Board for Scotland
Contact Address: Delta House, 50 West Nile Street Glasgow G1 2NP Scotland United Kingdom Tel: +44 141 225 6988; Fax: +44 141 221 3262
Contact Name:
Contact Email:
Copyright: Health Technology Board for Scotland (HTBS) (merged into NHS Quality Improvement Scotland (NHS QIS))
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.